STOCK TITAN

PDS Biotechnology Corporation (PDSB) Financials

PDSB NASDAQ
FY2025 annual
Net Income -$34.5M n/m YoY
EPS (Diluted) -$0.74 n/m YoY
Free Cash Flow -$27.8M n/m YoY
Operating Cash Flow -$27.8M n/m YoY
Market Cap $96.2M as of Nov 18, 2026
Price / Sales n/m no revenue reported
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 7.1x on $13.5M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 16, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PDSB SEC filings page.

This page shows PDS Biotechnology Corporation (PDSB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PDSB FY2025

The company remains loss-making and cash-consuming, while shrinking assets and a heavier liabilities burden reshape how it is financed.

FY2025 net loss was $34.5M against operating cash flow of -$27.8M, indicating accounting losses were translating into cash outflows rather than being mostly non-cash. Financing cash flow of $12.8M offset only part of that outflow, while liabilities reached 69.7% of assets; the business is funding ongoing development with a thinner capital base.

R&D of $19.0M exceeded SG&A of $12.5M in FY2025, showing the expense base remains oriented toward development rather than commercial overhead. The operating loss narrowed from $36.3M in FY2024 to $31.5M in FY2025, so the visible improvement coincided with lower reported operating expenses, not demonstrated revenue scale.

Between FY2023 and FY2025, liabilities rose from 56.0% to 69.7% of assets, indicating creditors represent a larger claim on a smaller balance-sheet base. The FY2025 current ratio of 3.0x indicates near-term asset coverage, but does not reverse the heavier liabilities claim.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for PDS Biotechnology Corporation, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
2/6

PDS Biotechnology Corporation passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing
N/A

PDS Biotechnology Corporation reported a net loss of $34.5M while operations used $27.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

PDS Biotechnology Corporation reported an operating loss of $31.5M against $5.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA
-$5.9M
YoYn/m
QoQn/m

PDS Biotechnology Corporation's EBITDA was -$5.9M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$7.6M
YoYn/m
QoQn/m
5Y CAGRn/m

PDS Biotechnology Corporation reported a net loss of $7.6M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.11

PDS Biotechnology Corporation earned -$0.11 per diluted share (EPS) in Q3 2026.

Revenue

Not reported for Q3 2026.

Cash & Balance Sheet

Cash & Debt
$15.2M
YoY-41.8%
QoQ+172.4%
5Y CAGR-26.2%
10Y CAGR-18.1%

PDS Biotechnology Corporation held $15.2M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
105M

PDS Biotechnology Corporation had 105M shares outstanding in Q3 2026.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-56.5%
YoY+38.8pp

PDS Biotechnology Corporation's quarterly ROE was -56.5% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 38.8 percentage points from the same quarter a year earlier.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$2.1M
YoY-55.2%
QoQ-37.2%

PDS Biotechnology Corporation invested $2.1M in research and development in Q3 2026. This represents a decrease of 55.2% from the same quarter a year earlier. Against the prior quarter it is down 37.2%.

Share Buybacks

Not reported for Q3 2026.

Capital Expenditures

Not reported for Q3 2026.

PDSB Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PDSB quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
R&D Expenses$2.1M-55.2%$3.3M-22.5%$3.5M-40.7%N/A$4.6M-32.7%$4.2M-7.0%$5.8M-13.0%N/A
SG&A Expenses$3.8M+7.9%$3.2M-5.3%$3.1M-6.4%N/A$3.6M+5.6%$3.4M-18.0%$3.3M-3.5%N/A
Operating Income-$5.9Mn/m-$6.5Mn/m-$6.5Mn/mN/A-$8.1Mn/m-$7.6Mn/m-$9.1Mn/mN/A
EBITDA-$5.9Mn/m-$6.5Mn/m-$6.5Mn/mN/A-$8.1Mn/m-$7.6Mn/m-$9.1Mn/mN/A
Interest Expense$1.8M+53.6%$3.4M+57.6%$1.0M+9.0%N/A$1.2M-5.3%$2.1M+80.5%$931K-20.8%N/A
Income Tax$0n/m$0n/m$0n/mN/A$0n/m$0n/m-$1.2Mn/mN/A
Net Income-$7.6Mn/m-$9.8Mn/m-$7.3Mn/m-$7.6Mn/m-$9.0Mn/m-$9.4Mn/m-$8.5Mn/m-$8.0Mn/m
EPS (Basic)-$0.11-$0.18n/m-$0.13n/m-$0.14n/m-$0.19n/m-$0.21n/m-$0.21n/m-$0.21n/m
EPS (Diluted)-$0.11-$0.18n/m-$0.13n/m-$0.14n/m-$0.19n/m-$0.21n/m-$0.21n/m-$0.21n/m
Diluted Shares (Avg)72M56M+21.3%55M+37.0%N/A47M+27.3%46M+25.1%41M+16.4%N/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.

PDSB Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PDSB quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'25FilingQ4'2410-K
Total Assets$18.6M-46.5%$8.8M-78.2%$24.7M-47.6%$30.5M-32.8%$34.7M-33.8%$40.5M-33.1%$47.0M-31.8%$45.4M-23.6%
Current Assets$18.4M-34.1%$7.0M-79.1%$22.9M-46.1%$28.3M-37.3%$27.9M-46.5%$33.6M-44.1%$42.5M-38.2%$45.1M-23.7%
Cash & Equivalents$15.2M-41.8%$5.6M-82.4%$21.7M-45.8%$26.7M-35.9%$26.2M-47.3%$31.9M-44.8%$40.0M-40.0%$41.7M-26.3%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$5.1M-79.9%$12.4M-49.5%$20.8M-15.8%$21.2M-19.4%$25.3M-17.1%$24.5M-17.1%$24.7M-22.5%$26.4M-20.8%
Current Liabilities$5.1M-61.9%$12.4M+7.3%$10.1M-44.4%$9.5M-44.5%$13.3M-27.3%$11.5M-26.4%$18.3M+21.3%$17.1M+25.4%
Non-Current Liabilities$1K-100.0%$9K-99.9%$10.6M+66.0%$11.8M+26.9%$11.9M-1.5%$13.0M-6.6%$6.4M-61.8%$9.3M-52.8%
Total Equity$13.5M+42.8%-$3.6M-122.4%$3.9M-82.6%$9.3M-51.3%$9.5M-57.0%$16.0M-48.4%$22.4M-39.9%$19.0M-27.3%
Retained Earnings-$241.3Mn/m-$233.7Mn/m-$224.0Mn/m-$216.6Mn/m-$209.0Mn/m-$200.0Mn/m-$190.6Mn/m-$182.1Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

PDSB Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PDSB quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$8.2Mn/m-$2.8Mn/m-$4.4Mn/m-$3.7Mn/m-$5.9Mn/m-$9.1Mn/m-$9.0Mn/m-$8.2Mn/m
Depreciation & Amortization$15K0.0%$15K0.0%$15K0.0%$15K0.0%$15K0.0%$15K0.0%$15K+5.0%$15K+5.0%
Stock-Based Compensation$840K-32.6%$1.1M+151.3%$1.2M-7.8%N/A$1.2M-29.9%$448K-75.1%$1.3M-23.1%N/A
Capital ExpendituresN/AN/AN/A$0n/m$0-100.0%N/AN/A$0n/m
Free Cash FlowN/AN/AN/A-$3.7Mn/m-$5.9Mn/mN/AN/A-$8.2Mn/m
Investing Cash FlowN/AN/AN/A$0n/m$0n/mN/AN/A$0n/m
Financing Cash Flow$17.9M+7309.7%-$13.3M-1432.6%-$680K-109.3%$4.2M+2340.1%$241K+1301.1%$996Kn/m$7.3M-63.4%$173K-98.4%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

PDSB Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PDSB quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Return on Equity-56.5%+38.8ppN/A-188.8%-150.8pp-81.8%-39.9pp-95.3%-46.5pp-59.1%-32.2pp-38.0%-9.4pp-41.8%-0.1pp
Return on Assets-41.0%-15.1pp-110.7%-87.4pp-29.8%-11.8pp-24.8%-7.3pp-26.0%-5.5pp-23.3%-9.5pp-18.1%-2.7pp-17.5%+0.8pp
Current Ratio3.62+1.5x0.57-2.3x2.26-0.1x2.98+0.3x2.09-0.7x2.92-0.9x2.33-2.2x2.64-1.7x
Liabilities-to-Equity0.38-2.3xN/A5.34+4.2x2.30+0.9x2.67+1.3x1.54+0.6x1.10+0.2x1.39+0.1x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
PDS Biotechnology Corporation PDSB FY2025 N/A -$34.5M N/A $96.2M —
MAIA Biotechnology, Inc. MAIA FY2025 N/A -$22.4M N/A $80.3M —
Cognition Therapeutics, Inc. CGTX FY2025 N/A -$23.5M N/A $57.1M —
Acrivon Therapeutics, Inc. ACRV FY2025 N/A -$77.9M N/A $66.9M —
Verrica Pharmaceuticals Inc. VRCA FY2025 $35.6M -$17.9M -50.3% $49.0M 66/100
Corbus Pharmaceuticals Holdings, Inc. CRBP FY2025 N/A -$78.5M N/A $56.6M —

Frequently Asked Questions

No, PDS Biotechnology Corporation (PDSB) reported a net loss of $34.5M in fiscal year 2025.

PDS Biotechnology Corporation (PDSB) reported diluted earnings per share of -$0.74 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

PDS Biotechnology Corporation (PDSB) had EBITDA of -$31.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

PDS Biotechnology Corporation (PDSB) has a return on equity of -372.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

PDS Biotechnology Corporation (PDSB) recorded an outflow of $27.8M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

PDS Biotechnology Corporation (PDSB) recorded an outflow of $27.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

PDS Biotechnology Corporation (PDSB) had $30.5M in total assets as of fiscal year 2025, including both current and long-term assets.

PDS Biotechnology Corporation (PDSB) reported no capital expenditure during fiscal year 2025.

PDS Biotechnology Corporation (PDSB) invested $19.0M in research and development during fiscal year 2025.

PDS Biotechnology Corporation (PDSB) had 56M shares outstanding as of fiscal year 2025.

PDS Biotechnology Corporation (PDSB) had a current ratio of 2.98 as of fiscal year 2025, which is generally considered healthy.

PDS Biotechnology Corporation (PDSB) had a liabilities-to-equity ratio of 2.30 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

PDS Biotechnology Corporation (PDSB) had a return on assets of -113.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

PDS Biotechnology Corporation (PDSB) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $96.2M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

PDS Biotechnology Corporation (PDSB) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $96.2M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, PDS Biotechnology Corporation (PDSB) held $26.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $27.8M over that year. Dividing the one by the other, the reported balance equals about 12 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

PDS Biotechnology Corporation (PDSB) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

PDS Biotechnology Corporation (PDSB) reported a net loss of $34.5M while operations used $27.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

PDS Biotechnology Corporation (PDSB) reported an operating loss of $31.5M against $5.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Back to top